<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490268</url>
  </required_header>
  <id_info>
    <org_study_id>PKPDHM-001</org_study_id>
    <secondary_id>2011-003648-31</secondary_id>
    <nct_id>NCT01490268</nct_id>
  </id_info>
  <brief_title>Pain Therapy After Elective Cardiac Surgery</brief_title>
  <acronym>PKPDHM-001</acronym>
  <official_title>Pharmacokinetic-pharmacodynamic Modeling of the Postoperative Pain Sensation During Patient-controlled Analgesia With Target-controlled Infusion of Hydromorphone, Taking Into Account the Interaction With Intraoperatively Administered Sufentanil for Elective Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine generation of a target controlled infusion model
      for the patient controlled analgesia with the strong analgesic, hydromorphone, after planned
      open heart surgery, during which the strong analgesic, sufentanil, was used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of sufentanil and hydromorphone</measure>
    <time_frame>48 hours</time_frame>
    <description>28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical Rating Scale for Clinical Pain</measure>
    <time_frame>8 hours</time_frame>
    <description>11 assessments of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total amount of hydromorphone</measure>
    <time_frame>8 hours</time_frame>
    <description>Cumulative dose of hydromorphone for patient-controlled analgesia with target-controlled infusion of hydromorphone for characterizing the analgesic requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Scale</measure>
    <time_frame>8 hours</time_frame>
    <description>11 assessments of the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Scale during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the sedation level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Sufentanil Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufentanil Low Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufentanil High Titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil, Hydromorphone</intervention_name>
    <description>Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone</description>
    <arm_group_label>Sufentanil Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil, Hydromorphone</intervention_name>
    <description>Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone</description>
    <arm_group_label>Sufentanil Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent,

          -  Ability to understand the nature of patient-controlled analgesia and other
             study-specific procedures,

          -  Elective cardiac surgery with thoracotomy and subsequent stay in the intensive care
             unit

        Exclusion Criteria:

          -  Use of MAO inhibitors in the last 14 days,

          -  Chronic alcoholism or drug addiction in medical history,

          -  Severe obstructive or restrictive pulmonal disorders in medical history,

          -  Severe hepatic and renal disorders in medical history,

          -  Hypothyroidism, pancreatitis in medical history,

          -  ASA IV,

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jeleazcov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Erlangen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jeleazcov C, Saari TI, Ihmsen H, Mell J, Fröhlich K, Krajinovic L, Fechner J, Schüttler J. Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. Anesthesiology. 2014 Feb;120(2):378-91. doi: 10.1097/ALN.0b013e3182a76d05.</citation>
    <PMID>23958818</PMID>
  </reference>
  <reference>
    <citation>Saari TI, Ihmsen H, Mell J, Fröhlich K, Fechner J, Schüttler J, Jeleazcov C. Influence of intensive care treatment on the protein binding of sufentanil and hydromorphone during pain therapy in postoperative cardiac surgery patients. Br J Anaesth. 2014 Oct;113(4):677-87. doi: 10.1093/bja/aeu160. Epub 2014 Jul 6.</citation>
    <PMID>25001621</PMID>
  </reference>
  <reference>
    <citation>Saari TI, Fechner J, Ihmsen H, Schüttler J, Jeleazcov C. Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC-MS/MS: application to clinical trial in patients undergoing open heart surgery. J Pharm Biomed Anal. 2012 Dec;71:63-70. doi: 10.1016/j.jpba.2012.07.025. Epub 2012 Jul 31.</citation>
    <PMID>22884788</PMID>
  </reference>
  <reference>
    <citation>Saari TI, Fechner J, Ihmsen H, Schüttler J, Jeleazcov C. Determination of total and unbound sufentanil in human plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetic study. J Pharm Biomed Anal. 2012 Jul;66:306-13. doi: 10.1016/j.jpba.2012.03.050. Epub 2012 Apr 3.</citation>
    <PMID>22522038</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic-pharmacodynamic modeling</keyword>
  <keyword>Patient-controlled analgesia</keyword>
  <keyword>Target-controlled infusion</keyword>
  <keyword>Hydromorphone</keyword>
  <keyword>Sufentanil</keyword>
  <keyword>after thoracotomy</keyword>
  <keyword>cardiac surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

